Data confirm accuracy of DecisionDx-UM and demonstrate impact of test results on patient care and follow-upContinue reading
Author Archive: AZBio
Sonoran Biosciences Wins SBIR Phase II Award for Sustained-Release Antibiotic Gel to Treat Prosthetic Joint Infections
PJI treatment costs U.S. health system $4 billion annually; grant funds research required to proceed to clinical trials
EPA Approves SenesTech’s Humane Pest Control for Rodent Population through Fertility Control
SenesTech Looks to Reduce the Use of Dangerous and Harmful Rodenticide Treatments
Mayo Clinic and ASU to form collaborative research teams
Mayo Clinic and Arizona State University’s (ASU) research leadership announce the launch of a new grant program that will team up research scientists and clinicians from both institutions to develop transformative solutions for patients.Continue reading
Growing up on an Amish Farm Protects Children Against Asthma, UAHS Collaborative Research Shows
House dust differences between Amish and Hutterite communities affect immune development and asthma risk, according to a study co-authored by University of Arizona Health Sciences researcher Dr. Donata Vercelli published Aug. 4 in the New England Journal of Medicine.Continue reading
$400,000 grant from the National Institute of Health (NIH) to test and refine a new antibacterial material,
Molded in clay: new antibacterials to kill germs
Calimmune CEO Louis Breton Named to PharmaVOICE 100 for 2016
Calimmune, Inc., a clinical-stage gene therapy company, is pleased to announce that its Chief Executive Officer, Louis Breton, has been selected by PharmaVOICE magazine as one of the top 100 most inspirational and extraordinary leaders in the life sciences industry for 2016.
Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in Stage I and II Cohort Study at 2016 AAD Summer Meeting
Study confirms DecisionDx-Melanoma accurately predicts metastatic risk in Stage I or Stage II patients who have no sign of disease beyond original tumorContinue reading
HTG Molecular Diagnostics Obtains CE IVD Mark for Its HTG EdgeSeq DLBCL Cell of Origin Assay and HTG EdgeSeq System
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that it has obtained CE-IVD marking for its HTG EdgeSeq DLBCL Cell of Origin Assay and next-generation sequencing (NGS) based HTG EdgeSeq system.Continue reading
UA Study of Lung Disorders Gets $11.4M Boost
The National Heart, Lung and Blood Institute program has granted $11.4 million to a project led by Dr. Joe G.N. “Skip” Garcia, the UA’s vice president for health sciences.Continue reading